JP2019507608A5 - - Google Patents

Download PDF

Info

Publication number
JP2019507608A5
JP2019507608A5 JP2018563769A JP2018563769A JP2019507608A5 JP 2019507608 A5 JP2019507608 A5 JP 2019507608A5 JP 2018563769 A JP2018563769 A JP 2018563769A JP 2018563769 A JP2018563769 A JP 2018563769A JP 2019507608 A5 JP2019507608 A5 JP 2019507608A5
Authority
JP
Japan
Prior art keywords
hla
gene
allele
cancer cell
class
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018563769A
Other languages
English (en)
Japanese (ja)
Other versions
JP6901505B2 (ja
JP2019507608A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/019757 external-priority patent/WO2017147600A1/en
Publication of JP2019507608A publication Critical patent/JP2019507608A/ja
Publication of JP2019507608A5 publication Critical patent/JP2019507608A5/ja
Application granted granted Critical
Publication of JP6901505B2 publication Critical patent/JP6901505B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018563769A 2016-02-25 2017-02-27 全細胞がんワクチンおよびその選択のための方法 Active JP6901505B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662299674P 2016-02-25 2016-02-25
US62/299,674 2016-02-25
US201662425027P 2016-11-21 2016-11-21
US62/425,027 2016-11-21
PCT/US2017/019757 WO2017147600A1 (en) 2016-02-25 2017-02-27 Whole-cell cancer vaccines and methods for selection thereof

Publications (3)

Publication Number Publication Date
JP2019507608A JP2019507608A (ja) 2019-03-22
JP2019507608A5 true JP2019507608A5 (https=) 2020-04-02
JP6901505B2 JP6901505B2 (ja) 2021-07-14

Family

ID=59685619

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018563769A Active JP6901505B2 (ja) 2016-02-25 2017-02-27 全細胞がんワクチンおよびその選択のための方法

Country Status (9)

Country Link
US (2) US11559574B2 (https=)
EP (1) EP3419657A4 (https=)
JP (1) JP6901505B2 (https=)
CN (1) CN109069603A (https=)
AU (3) AU2017224232B2 (https=)
CA (2) CA3015080A1 (https=)
IL (1) IL261354A (https=)
NZ (1) NZ745327A (https=)
WO (1) WO2017147600A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3419657A4 (en) 2016-02-25 2019-11-06 Briacell Therapeutics Corp. CELLULAR CANCER VACCINES AND METHOD FOR SELECTION THEREOF
AU2018378201A1 (en) * 2017-12-04 2020-05-21 Heat Biologics, Inc. Production of cell-based vaccines
EP3727467A4 (en) * 2017-12-22 2021-12-01 Centivax, Inc. MAJOR HISTOCOMPATIBILITY COMPLEX (CMH) COMPOSITIONS AND CORRESPONDING PROCEDURES FOR USE
CN108175853A (zh) * 2018-01-24 2018-06-19 上海赛群生物科技有限公司 一种肿瘤细胞疫苗及其制备方法
CN108486038B (zh) * 2018-03-21 2021-08-27 中国人民解放军第四军医大学 一种构建脂肪干细胞膜片的方法及应用
EP4582440A3 (en) * 2018-12-21 2025-10-08 The Regents of the University of California Il-10-containing vaccines and uses thereof
AU2020395765A1 (en) 2019-12-03 2022-06-16 Neuvogen, Inc. Tumor cell vaccines
CN110938630B (zh) * 2019-12-20 2023-07-28 中国人民解放军第四军医大学 人b3gnt5基因的用途及相关产品
US20250020652A1 (en) * 2021-11-18 2025-01-16 Partner Therapeutics, Inc. Granulocyte-macrophage colony-stimulating factor-based cancer treatments
IL315361A (en) 2022-03-03 2024-11-01 Briacell Therapeutics Corp Cancer vaccines and methods of use thereof
CN115433734B (zh) * 2022-06-01 2025-03-04 北京奇糖科技有限公司 核酸片段及其在制备肿瘤疫苗中的应用
CN117990593A (zh) * 2024-01-31 2024-05-07 南昌铭硕生科生物工程有限公司 一种流式多因子分析系统及其分析方法
WO2025171109A1 (en) 2024-02-07 2025-08-14 Briacell Therapeutics Corp. Cancer vaccines expressing post-translational modified antigens and methods of use thereof
CN118207320A (zh) * 2024-04-28 2024-06-18 复旦大学附属中山医院 Hla-c*04:01基因的新用途及检测试剂盒
CN118207319A (zh) * 2024-04-28 2024-06-18 复旦大学附属中山医院 Hla-a*03:04基因的新用途及检测试剂盒
WO2026068517A1 (en) * 2024-09-24 2026-04-02 Universiteit Gent Cancer immunotherapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105008A0 (en) * 1992-03-13 1993-07-08 Yeda Res & Dev Double transfectants of mhc genes as cellular vaccines for immunoprevention of tumor metastasis
US5858776A (en) * 1993-11-03 1999-01-12 Repligen Corporation Tumor cells with increased immunogenicity and uses therefor
JP2002536996A (ja) * 1999-02-22 2002-11-05 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ チロシンキナーゼ受容体ＥｐｈＡ３抗原ペプチド
US7674456B2 (en) 2004-06-14 2010-03-09 Charles Wiseman Breast cancer cell lines and uses thereof
WO2006081629A1 (en) 2005-02-04 2006-08-10 Stem Cell Australia Pty Ltd Adenoviral vectors comprising a nucleic acid encoding a mhc class i molecule and the use of such vectors in cancer therapy.
WO2006135454A1 (en) * 2005-06-08 2006-12-21 Saint Vincent Medical Center, A California Corporation Novel cancer cell lines and uses thereof
US20080020386A1 (en) 2006-03-29 2008-01-24 Medigen Biotechnology Corporation Methods and apparatus for genotyping
US7807186B2 (en) * 2007-01-17 2010-10-05 University Of Maryland, Baltimore County Tumor cells from immune privileged sites as base cells for cell-based cancer vaccines
WO2010045573A2 (en) 2008-10-17 2010-04-22 University Of Miami Tumor vaccine
AU2012257377B2 (en) 2011-05-17 2017-09-07 Hadasit Medical Research Services And Development Ltd. Allogeneic tumor cell vaccination
EP3419657A4 (en) 2016-02-25 2019-11-06 Briacell Therapeutics Corp. CELLULAR CANCER VACCINES AND METHOD FOR SELECTION THEREOF

Similar Documents

Publication Publication Date Title
JP2019507608A5 (https=)
ES2591029T3 (es) Péptidos WT-1 inmunogénicos y métodos para su uso
Tykodi et al. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens
Leung Use of NK cell activity in cure by transplant
Zilberberg et al. Strategies for the identification of T cell–recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation
Bernstein et al. Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells
US20210023163A1 (en) Activation and expansion of nkg2c+ nk cells
WO2020021045A3 (en) Therapeutic preparations of gamma-delta t cells and natural killer cells and methods for manufacture and use
CN110997903A (zh) 用于癌症治疗的t细胞的活化方法
JP2020532957A5 (https=)
JP2020532956A5 (https=)
JPWO2014042226A1 (ja) 抗原特異的ヘルパーｔ細胞レセプター遺伝子
Xu et al. Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma
JP2021530501A5 (https=)
JP2024051157A5 (https=)
JP2021507924A5 (https=)
Ozdilli et al. The frequency of HLA class I and II alleles in Turkish childhood acute leukaemia patients
Nowak et al. Epstein‐Barr virus infections are strongly dependent on activating and inhibitory KIR‐HLA pairs after T‐cell replate unrelated hematopoietic stem cell transplantation, the principles, and method of pairing analysis
Gao et al. Immunopotentiating effect of lentinan on chicks and its inhibitory effect on Marek's disease virus infection
Fousteri et al. Increased memory conversion of naive CD8 T cells activated during late phases of acute virus infection due to decreased cumulative antigen exposure
Kayser et al. Severe ankylosing spondylitis and diffuse systemic sclerosis: case report of a genetic trap
Cervera et al. Human leukocyte antigen–G allele polymorphisms have evolved following three different evolutionary lineages based on intron sequences
Emtestam et al. Multiple basal cell carcinomas: no association with HLA‐DRB, HLA‐DQAI or HLA‐DQBI in Swedish patients
CA2475784C (en) A method for identification and determination of hypersensitivity of a patient to abacavir
JP6401445B2 (ja) 造血幹細胞移植用の組合せ細胞製剤および生着促進剤並びにこれらの製造方法